Thursday, May 10, 2018
CONTINENTAL BREAKFAST
7:00 - 8:00  
Introduction
8:00 - 8:15

Introduction to the Day’s Proceedings

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada

SESSION 5:
Prevention of HBOC
8:15 - 9:45

CHAIR: Clare Turnbull, MBBS, PhD, Genomics England and Queen Mary University of London, London, UK

8:15 - 8:35

Non-surgical breast cancer prevention in BRCA1/2 carriers: What do we know?

Joanne Kotsopoulos, PhD, Women's College Research Institute; University of Toronto, Toronto, ON, Canada

8:35 - 8:55

Preventing cancer via BRCA population testing in unaffected women – the Israeli Experience

Ephrat Levy-Lahad, MD, Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel

8:55 - 9:05

Proffered paper 1
Oral contraceptive use and breast cancer risk: Retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study

Lieske Schrijver, MSc, PhD Student, Netherlands Cancer Institute, Amsterdam, The Netherlands>

9:05 - 9:15

Proffered paper 2
Population genetic testing for breast and ovarian cancer susceptibility – the Australian experience

Alison Trainer, FRACP, PhD, Peter MacCallum Cancer Centre, Parkville, VIC, Australia

9:15 - 9:25

Proffered paper 3
The Screen Project: A populations-based genetic testing for BRCA1/2 genes in Canada

Mohammad Reza Akbari, MD, PhD, Women's College Hospital, University of Toronto, Toronto, ON, Canada

9:25 - 9:45

Question and discussion period (all speakers)

BREAK
9:45 - 10:15  
SESSION 6:
Treatment of HBOC
10:15 - 11:45

CHAIR: Mark Robson, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

10:15 - 10:35

Treatment of BRCA-related breast cancer: an update

Nicholas Turner, MBBS, PhD, The Royal Marsden Hospital and The Institute of Cancer Research, London, UK

10:35 - 10:55

Treatment of ovarian cancer with PARP inhibitors: How important is BRCA status and how should we determine it?

Amit Oza, MD, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

10:55 - 11:05

Proffered paper 1
The impact of germline BRCA mutation on young onset breast cancer treatment outcomes – results from the POSH study

Diana Eccles, MB, ChB, MRCP, FRCP, University of Southampton, UK

11:05 - 11:15

Proffered paper 2
Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations Christine Kobelka, MSc, Kaiser Permanente, San Francisco, CA, USA

Christine Kobelka, MSc, Kaiser Permanente, San Francisco, CA, USA

11:15 - 11:25

Proffered paper 3
Outcomes associated with rapid genetic testing for BRCA1 and BRCA2 at time of breast cancer diagnosis

Kelly Metcalfe, PhD, Women's College Research Institute; University of Toronto, Toronto, ON, Canada

11:25 - 11:45

Question and discussion period (all speakers)

LUNCH
11:45 - 13:15  


SESSION 7:
New challenges in Genetic Counselling
13:15 - 14:45

CHAIR: Lisa Madlensky, PhD, CGC, Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA

13:15 - 13:35

Alternate service delivery models in the area of NGS

Adam Buchanan, MS, MPH, LGC, Genomic Medicine Institute, Geisinger Health System, Danville, PA, USA

13:35 - 13:55

Ethical / legal issues in the current Genetic Counselling / Genetic Testing landscape

Bartha Maria Knoppers, PhD, Centre of Genomics and Policy, McGill University, Montréal, QC, Canada

13:55 - 14:05

Proffered paper 1
Gen Y and hereditary breast/ovarian cancer: Understanding the experiences and information gaps of young adults

Alison Young, B Psych Sc (Honours), PhD Candidate, The University of Sydney, Sydney, NSW, Australia

14:05 - 14:15

Proffered paper 2
Modified panel-based genetic counselling for ovarian cancer susceptibility: A randomized non-inferiority trial

Jeanna McCuaig, MSc, Princess Margaret Cancer Centre - University Health Network, Toronto, ON, Canada

14:15 - 14:25

Proffered paper 3
BRCA1/BRCA2 population screening in Ashkenazi Jews: Long-term impact and health behaviors

Sari Lieberman, PhD, Shaare Zedek Medical Center, Jerusalem, Israel

14:25 - 14:45

Question and discussion period (all speakers)

POSTER SESSION 2
14:45 - 16:30
SESSION 8:
Special Interest Groups (SIGs)
16:30 - 18:30

SIG 1:

Moderate Risk Genes: risks, counselling and outcomes

In this session, the panelists will survey the latest data on moderate risk breast and ovarian cancer genes in the areas of risk, possible effects on treatment choice and other relevant topics. Attendees will be encouraged to send in interesting examples in advance for discussion at the SIG.

  • Mark Robson, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA;

  • Ian Campbell, PhD, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;

  • Lisa Madlensky, PhD, CGC, Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA

SIG 2:

Next Generation Tumor Sequencing: beyond tumor genotyping

In this session, after surveying the current landscape of tumor NGS, the panelists will discuss incidental findings, BRCA1/2 mutations in children and other “germline dilemmas” arising from tumor testing.

  • Jorge Reis-Filho, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA;

  • Britta Weigelt, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA;

  • Clare Turnbull, MBBS, PhD, Genomics England and Queen Mary University, London, UK;

  • Adam Buchanan, MS, MPH, LGC, Genomic Medicine Institute, Geisinger Health System, Danville, PA, USA

  • Bartha Maria Knoppers, PhD, Centre of Genomics and Policy, McGill University, Montréal, QC, Canada

SIG 3:

Surgery for HBOC and its aftermath

In this session, the discussants will discuss the key issues faced by women who undergo either preventive or therapeutic surgical intervention for HBOC-associated reasons. The session will not focus deeply on technical details, but will update participants on the broader aspects of these topics.

  • Bethan Powell, MD, Kaiser Permanente, San Francisco, CA, USA;

  • Mary Gemignani, MD, MPH, FACS, Memorial Sloan-Kettering Cancer Center, New York, NY, USA;

  • Jennifer Blake, MD, The Society of Obstetricians and Gynaecologists of Canada, Ottawa, ON, Canada

SIG 4:

Next Generation Genetic Counseling - Tools for Challenging Psychosocial Cases

In this session, the discussants will review challenging cases from a psychosocial perspective and offer strategies based on current behavioral theories.

  • Karen Hurley, PhD, Cleveland Clinic, Cleveland, OH, USA;

  • Wendy McKinnon, MS, CGC, University of Vermont Cancer Center, Burlington, VT, USA